Physician profile
Erik W Oconnell
NPI 1891085122
$27,223.47
in general payments reported to CMS, 2019-2025
16 companies · $726 in 2025
The $726 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $148 · 2021: $711 · 2022: $11K · 2023: $13K · 2024: $698 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $2,626 · Travel and Lodging: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,700.00 |
| Food and Beverage | $2,626.03 |
| Travel and Lodging | $277.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $12,585.93 | 2022-2024 | Taltz |
| Janssen Biotech, INC. | $8,929.57 | 2021-2025 | Tremfya |
| Amgen INC. | $1,585.88 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Horizon Therapeutics Plc | $1,276.93 | 2021-2022 | |
| Abbvie INC. | $954.23 | 2019-2025 | |
| Ucb, INC. | $520.76 | 2022-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $440.28 | 2020-2024 | Benlysta |
| Janssen Scientific Affairs, LLC | $260.67 | 2021-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $145.63 | 2021-2023 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $141.05 | 2021-2025 | Orencia |
| Cardinal Health 110 LLC | $100.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.27 | 2021 | |
| Genzyme Corporation | $90.48 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $66.11 | 2021-2025 | |
| Organon LLC | $17.62 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $17.06 | 2023 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Oconnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.